It’s experienced steady and strong growth over its history with many companies investing large amounts of cash into the development of new products. Biomaterials science encompasses elements of drugs, biology, chemistry, tissue engineering and materials science. Tissue engineering may be a biomedical ...
The advancement of AI into scientific laboratories is opening new possibilities for biomedical knowledge. New AI tools have implications not only in how expert knowledge is produced, tested and validated, but also in how problems and hypothesis are designed in health innovation such as bioengineered d...
the time-consuming procedure of overseas acceptance of products affects the import and export of items. Due to the significant lead time necessary for international certification examinations, doing business in the overseas market is a key challenge for companies. As a result of the delay in product...
After the patent of alginate extraction from algae was granted in 1930s, alginate had been extracted in large scale from brown algae (Phaeophyceae sp.) such as Laminaria hyperborea, Laminaria digitata, Laminaria japonica, Ascophyllum nodosum, and Macrocystis pyrifera [19]. Chemical companies around ...
Hengrui, as one of the leading pharmaceutical companies in innovation, has achieved continuous improvement in its MSCI ESG rating to "A" level, placing it at the forefront of the pharmaceutical industry in China. Oct 08, 2023 12:28 PM Briefing Jun 23, 2022 10:15 AM · Healthcare Huamei...
Thus, various pharmaceutical companies are exploring antibacterial fields to search for effective and more powerful products [4]. Therefore, former last-resort antibacterial could be a choice by medical practitioners as the first-line therapy to fill in the gap of antibiotics. Table 1 presents the ...
Centre for Innovation in Medical Engineering (CIME), Faculty of Engineering, University of Malaya, 50603 Kuala Lumpur, Malaysia 3 Faculty of Science, Technology, Engineering and Mathematics, INTI International University, 71800 Nilai, Negeri Sembilan, Malaysia 4 Faculty-Electronics Engineering, Ruwais Col...
Indeed, the possible development of impurities and changes in the chemical or quantity of active drug species at different phases such as the production, transportation, or storage, makes them redundant and dangerous for human health; therefore, medical sectors and pharmaceutical companies need precise...
at least 570 therapeutic mAbs have been studied in clinical trials by commercial companies [2], and 79 therapeutic mAbs have been approved by the United States Food and Drug Administration (US FDA) and are currently on the market [3], including 30 mAbs for the treatment of cancer (Table1)...
Finally, and in particular, in a joint effort to develop novel devices, clinicians and medical device companies could also use them to develop optimised protocols using existing or new devices designed to fit into clinical workflow with minimal effort. This aspect is especially important wherever hum...